- CRISPR Therapeutics (NASDAQ:CRSP) is up 4% premarket on apparent reaction to the news that gene editing technology CRISPR/Cas9 has been employed for the first time in human offspring, a move that, if verified, is certain to stoke global controversy.
- A Chinese researcher, He Jiankui, supposedly used CRISPR/Cas9 to decommission an HIV-related gene called CCR5 in embryos for seven couples during fertility treatments. Two girls from the seven were recently born, both healthy.
- Related tickers: (NASDAQ:NTLA)(NASDAQ:EDIT)
-
Update: Rice University has opened an investigation into the involvement of faculty member Michael Deem in controversial research. He served as an advisor to Jiankui when he was a graduate student there.